Medpace Holdings, Inc. MEDP
Composite 61/100; the shares have moved about 50% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 24/100 — a strong mark against it.
Quality ranks 84/100 — a strong point in its favour. Growth ranks 70/100 — a moderate point in its favour. Balance-sheet strength ranks 66/100 — a moderate point in its favour.
Valuation ranks 24/100 — a strong mark against it.
What the company does Medpace Holdings provides full-service clinical development services—Phase I–IV trials, central labs, regulatory, and post-marketing support—across 6 continents for pharma, biotech, and medical-device sponsors.
Key financials High-margin model: gross 72.3%, operating 20.8%, net 17.7% margins. ROE 162.2%, ROA 20.1%, ROCE 94.6%. Revenue +17.2%, EPS +37.1% y/y. Debt/equity 0.33, net-debt/EBITDA –0.59, current ratio 0.73.
Stock health Momentum: +39.82% (3m), –3.28% (6m), +29.11% (12m); –14.69% below 52-week high. RSI(14) 61.50. Sidera overall 61.8 (“excellent quality, richly valued”).
Price vs fair value Medpace trades at a PREMIUM of 13.10% to our fair-value estimate of 502.41 and a discount of 0.61% to the analyst 12-month target of 581.83. - Quality pillar 83.2 signals durable franchise strength (Sidera). - Valuation percentile 27.5/100 flags rich multiples (P/E 35.33, EV/EBITDA 26.83). - Recent bullish coverage highlights growth momentum (Zacks, 2026-07-27). - Watchlist inclusion underscores cash-rich profile (StockStory, 2026-07-31).
Looking forward Forward P/E 35.71 implies continued premium pricing pending execution on backlog growth and margin stability.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.